Extracellular BRICK1 drives heart repair after myocardial infarction in mice.
Summary
This mechanistic study identifies the microprotein BRICK1 as a necessary extracellular cue for angiogenesis after myocardial infarction. BRICK1 is preferentially expressed in myeloid cells, relocates extracellularly after infarction in mice and humans, and is released during myeloid cell death, revealing an unexpected extracellular role for a WAVE-complex subunit.
Key Findings
- BRICK1 (75-aa microprotein) is indispensable for post-infarction angiogenesis in reperfused mouse MI.
- BRICK1 is preferentially expressed in myeloid cells and relocates to the extracellular space after MI in mice and humans.
- BRICK1 is not actively secreted but is released during myeloid cell death, revealing a novel extracellular role for a WAVE complex subunit.
Clinical Implications
While preclinical, BRICK1 could serve as a biomarker or therapeutic target to enhance angiogenesis and limit scarring after myocardial infarction. Translation will require clarifying dosing, delivery, and safety of modulating extracellular BRICK1 or its downstream pathways.
Why It Matters
Revealing an extracellular function for BRICK1 establishes a novel myeloid–endothelial axis controlling post-infarction angiogenesis, opening a therapeutic avenue targeting microproteins in cardiac repair.
Limitations
- Preclinical study; translational efficacy and safety in humans remain untested
- Quantitative dosing–response relationships and downstream targets were not fully defined in the abstract
Future Directions
Define downstream receptors/pathways of extracellular BRICK1, characterize pharmacology for agonism/antagonism, and test regenerative efficacy in large-animal MI models before early-phase clinical studies.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical mechanistic study using animal models and human samples
- Study Design
- OTHER